Izocet ampoules 0.1% 10 ml. №10

Description

Izocet ampoules Storage
active substance: isosorbide dinitrate;

1 ml of solution contains 1.0 mg of isosorbide dinitrate;

Excipients: sodium chloride, water for injections, sodium hydroxide 2M solution, hydrochloric acid 1M solution.

Izocet ampoules Dosage form
Solution for infusion.

Basic physical and chemical properties: transparent colorless liquid.

Izocet ampoules Pharmacotherapeutic group
Drugs that affect the cardiovascular system. Cardiac drugs. Vasodilators used in cardiology. Organic nitrates. ATX code C01D A08.

Pharmacological properties
Pharmacodynamics

Isosorbide dinitrate has a relaxing effect on vascular smooth muscle, causing them to vasodilate. This applies to both peripheral veins and arteries. This effect promotes the deposition of blood in the veins and reduces the volume of venous return to the heart; this reduces ventricular end-diastolic pressure and volume (preload). The effect on the arteries, and at higher doses – on the arterioles, reduces systemic vascular resistance (postload). This, in turn, reduces the work of the heart. The effect on both preload and postload reduces the heart’s need for oxygen. In addition, isosorbide dinitrate causes redistribution of blood flow to the subendocardial parts of the heart if coronary circulation is partially impaired by atherosclerotic lesions. This effect may be due to selective dilatation of large coronary vessels. Dilatation of collateral arteries caused by nitrates may improve poststenotic myocardial perfusion. Nitrates widen the lumen at the site of eccentric stenosis because they have the ability to counteract possible constrictive factors that affect the partially preserved smooth muscle of the coronary vessels at the site of narrowing. In addition, nitrates reduce coronary spasm.

Indication

Symptomatic treatment of unstable angina in addition to standard therapy, long-term therapy of vasospastic angina (Princemetal angina);
acute left ventricular heart failure of various etiologies (weakness of the heart muscle with dysfunction of the left ventricle);
acute myocardial infarction.

Contraindication

Hypersensitivity to isosorbide dinitrate, other nitrate compounds or other components of the drug;
acute circulatory failure (shock, collapse);
cardiogenic shock (except in cases when the final diastolic pressure of the left ventricle is maintained at a sufficient level due to appropriate measures);
hypertrophic obstructive cardiomyopathy;
constrictive pericarditis;
cardiac tamponade;
severe arterial hypotension (systolic blood pressure below 90 mm Hg);
severe hypovolemia;
severe anemia;
The drug should not be used during therapy with phosphodiesterase-5 inhibitors (eg sildenafil, vardenafil, tadalafil) – see sections “Features of use” and “Interaction with other drugs”;
soluble guanylate cyclase stimulant riociguate should not be used during nitrate therapy (see Interaction with other medicinal products and other forms of interaction);
hemorrhagic stroke;
head injury;
diseases accompanied by an increase in intracranial pressure (however, until now, an additional increase in intracranial pressure was observed only after intravenous administration of high doses of glyceryl trinitrate);
aortic and / or mitral stenosis;
angle-closure glaucoma;
hypothermia.